What is the appropriate treatment for a fungal infection?

Treatment of Fungal Infections

For invasive candidiasis and candidemia, echinocandins (caspofungin, micafungin, or anidulafungin) are the first-line treatment for most patients, with fluconazole reserved for less critically ill patients without recent azole exposure. 1

Invasive Candidiasis and Candidemia

Initial Therapy Selection

For critically ill or moderately severe patients:

• Echinocandins are preferred 1:
  • Caspofungin: 70 mg loading dose, then 50 mg daily 1
  • Micafungin: 100 mg daily 1
  • Anidulafungin: 200 mg loading dose, then 100 mg daily 1
• Lipid formulation amphotericin B (LFAmB) 3-5 mg/kg daily is an alternative 1

For less critically ill patients without recent azole exposure:

• Fluconazole is reasonable: 800 mg (12 mg/kg) loading dose, then 400 mg (6 mg/kg) daily 1

Species-Specific Considerations

C. glabrata infections:

• Echinocandins are strongly preferred 1
• LFAmB is less attractive but effective 1

C. parapsilosis infections:

• Fluconazole or LFAmB preferred over echinocandins 1

C. krusei infections:

• Echinocandin, LFAmB, or voriconazole recommended 1

Critical Management Steps

Catheter removal is mandatory:

• Strongly recommended for nonneutropenic patients 1
• Should be considered for neutropenic patients 1

Treatment duration:

• Continue for 2 weeks after documented bloodstream clearance AND resolution of symptoms 1
• In neutropenic patients, also wait for neutropenia resolution 1

Oropharyngeal Candidiasis

For mild disease:

• Clotrimazole troches 10 mg 5 times daily for 7-14 days 1
• Alternative: Nystatin suspension 4-6 mL 4 times daily 1

For moderate to severe disease:

• Oral fluconazole 100-200 mg daily for 7-14 days 1

For fluconazole-refractory disease:

• Itraconazole solution 200 mg once daily OR posaconazole suspension 400 mg twice daily for 3 days then 400 mg daily, up to 28 days 1
• Alternatives: voriconazole 200 mg twice daily OR intravenous echinocandin 1

Esophageal Candidiasis

First-line therapy:

• Oral fluconazole 200-400 mg (3-6 mg/kg) daily for 14-21 days 1

For patients unable to tolerate oral therapy:

• Intravenous fluconazole 400 mg (6 mg/kg) daily OR echinocandin (micafungin 150 mg daily, caspofungin 70 mg loading then 50 mg daily, or anidulafungin 200 mg daily) 1

For fluconazole-refractory disease:

• Itraconazole solution 200 mg daily OR voriconazole 200 mg (3 mg/kg) twice daily for 14-21 days 1
• Alternatives: echinocandin for 14-21 days OR amphotericin B deoxycholate 0.3-0.7 mg/kg daily for 21 days 1

Neonatal Candidiasis

For disseminated candidiasis:

• Amphotericin B deoxycholate 1 mg/kg daily is first-line 1
• Fluconazole 12 mg/kg daily is reasonable if no prior fluconazole prophylaxis 1
• LFAmB 3-5 mg/kg daily can be used if urinary tract involvement excluded 1
• Echinocandins reserved for salvage therapy or when resistance/toxicity precludes other agents 1

Essential diagnostic workup:

• Lumbar puncture and dilated retinal examination mandatory 1
• Imaging of genitourinary tract, liver, and spleen if persistent positive cultures 1

Treatment duration:

• 2 weeks after bloodstream clearance and symptom resolution 1
• 3 weeks for disseminated disease 1

Empirical Therapy in Critically Ill Patients

For nonneutropenic ICU patients with suspected candidiasis:

• Echinocandins preferred if recent azole exposure, moderately/severely ill, or high risk for C. glabrata/C. krusei 1
• Fluconazole acceptable if no recent azole exposure and less critically ill 1

For neutropenic patients:

• LFAmB 3-5 mg/kg daily, caspofungin (70 mg loading, then 50 mg daily), or voriconazole (6 mg/kg IV twice daily for 2 doses, then 3 mg/kg twice daily) 1
• Avoid azoles if patient received azole prophylaxis 1

Common Pitfalls

Avoid these errors:

• Using fluconazole empirically in patients with recent azole exposure or severe sepsis 1
• Failing to remove central venous catheters in candidemia 1
• Stopping therapy before 2 weeks post-clearance 1
• Using echinocandins for CNS or ocular candidiasis (poor penetration) 1
• Treating Candida respiratory colonization (rarely requires antifungal therapy) 1

Emerging Considerations

The 2025 ECMM global guidance emphasizes that echinocandins, including the new agent rezafungin, remain first-line for candidemia and invasive candidiasis except CNS and ocular infections due to broad activity and safety 1. New agents like ibrexafungerp and oteseconazole now complement treatment options for superficial candidiasis 1. Antifungal stewardship is crucial for appropriate use and controlling resistance, particularly with emerging pathogens like C. auris 1.